The Asia-Pacific's growing and maturing biopharmaceutical industry offers tremendous business and investment opportunities. China, India, Australia, Taiwan South Korea and Japan have already established themselves as serious players, committing significant amounts to investment in the next five to ten years to strengthen their capabilities.
The level of mergers and acquisitions (M&A) is expected to pick up and investors can expect a wave of cross-border consolidations and initial public offerings (IPOs). We have compiled a series of ebooks showcasing Asia's most promising biotech companies who are looking for partners and investors to assist them in their funding and co-development needs. In this Part II series of Asia's most promising biotechs and their pipelines, we have put together 23 new Asian biotechs for your review.
If you missed Asia's most promising biotechs & their pipelines [Part I] you can download it here >